StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) stock

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)

Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –

Vertex Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vertex Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $12.59B, up 10.2% year over year. For fiscal 2025 it was $12.00B, up 8.9% from the year before. Over ten years it grew 27.8% a year on average. The highest annual figure on record is $12.00B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.00B+8.9%
FY2024Dec 31, 2024$11.02B+11.7%
FY2023Dec 31, 2023$9.87B+10.5%
FY2022Dec 31, 2022$8.93B+17.9%
FY2021Dec 31, 2021$7.57B+22.1%
FY2020Dec 31, 2020$6.21B+49.1%
FY2019Dec 31, 2019$4.16B+36.6%
FY2018Dec 31, 2018$3.05B+22.5%
FY2017Dec 31, 2017$2.49B+46.2%
FY2016Dec 31, 2016$1.70B+64.9%
FY2015Dec 31, 2015$1.03B+77.9%
FY2014Dec 31, 2014$580.42M-52.1%
FY2013Dec 31, 2013$1.21B-20.6%
FY2012Dec 31, 2012$1.53B+8.3%
FY2011Dec 31, 2011$1.41B+883.9%
FY2010Dec 31, 2010$143.37M+40.7%
FY2009Dec 31, 2009$101.89M-41.9%
FY2008Dec 31, 2008$175.50M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.33B+12.5%
Q1 FY2026Mar 31, 2026$2.99B+7.8%
Q4 FY2025Dec 31, 2025$3.19B+9.5%
Q3 FY2025Sep 30, 2025$3.08B+11.0%
Q2 FY2025Jun 30, 2025$2.96B+12.1%
Q1 FY2025Mar 31, 2025$2.77B+3.0%
Q4 FY2024Dec 31, 2024$2.91B+15.7%
Q3 FY2024Sep 30, 2024$2.77B+11.6%
Q2 FY2024Jun 30, 2024$2.65B+6.1%
Q1 FY2024Mar 31, 2024$2.69B+13.3%
Q4 FY2023Dec 31, 2023$2.52B+9.3%
Q3 FY2023Sep 30, 2023$2.48B+6.4%
Q2 FY2023Jun 30, 2023$2.49B+13.5%
Q1 FY2023Mar 31, 2023$2.37B+13.2%
Q4 FY2022Dec 31, 2022$2.30B+11.1%
Q3 FY2022Sep 30, 2022$2.33B+17.7%
Q2 FY2022Jun 30, 2022$2.20B+22.5%
Q1 FY2022Mar 31, 2022$2.10B+21.6%
Q4 FY2021Dec 31, 2021$2.07B+27.3%
Q3 FY2021Sep 30, 2021$1.98B+29.0%
Q2 FY2021Jun 30, 2021$1.79B+17.6%
Q1 FY2021Mar 31, 2021$1.72B+13.8%
Q4 FY2020Dec 31, 2020$1.63B+15.2%
Q3 FY2020Sep 30, 2020$1.54B+62.0%
Q2 FY2020Jun 30, 2020$1.52B+62.0%
Q1 FY2020Mar 31, 2020$1.52B+76.5%
Q4 FY2019Dec 31, 2019$1.41B+62.4%
Q3 FY2019Sep 30, 2019$949.83M+21.1%
Q2 FY2019Jun 30, 2019$941.29M+25.1%
Q1 FY2019Mar 31, 2019$858.44M+34.0%
Q4 FY2018Dec 31, 2018$870.11M+33.5%
Q3 FY2018Sep 30, 2018$784.54M+35.7%
Q2 FY2018Jun 30, 2018$752.16M+38.2%
Q1 FY2018Mar 31, 2018$640.80M-10.3%
Q4 FY2017Dec 31, 2017$651.63M+42.1%
Q3 FY2017Sep 30, 2017$578.17M+39.7%
Q2 FY2017Jun 30, 2017$544.14M–
Q1 FY2017Mar 31, 2017$714.72M–
Q4 FY2016Dec 31, 2016$458.71M–
Q3 FY2016Sep 30, 2016$413.78M–

More Vertex Pharmaceuticals figures

See a number that looks wrong?